Try our beta test site

Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine

This study has been completed.
Information provided by:
Shantha Biotechnics Limited Identifier:
First received: February 6, 2008
Last updated: June 24, 2009
Last verified: June 2009
The purpose of this study is to evaluate the safety and immunogenicity of an indigenously developed liquid pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib) combination vaccine in healthy Indian infants as a part of the routine immunization in accordance with the EPI schedule.

Condition Intervention Phase
Hepatitis B
Haemophilus Influenzae Type B
Biological: Shan5
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants.

Resource links provided by NLM:

Further study details as provided by Shantha Biotechnics Limited:

Primary Outcome Measures:
  • Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccine. [ Time Frame: 4 months ]

Secondary Outcome Measures:
  • Solicited and unsolicited local and systemic adverse events following vaccination [ Time Frame: 4 months ]

Enrollment: 160
Study Start Date: March 2008
Study Completion Date: May 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Shan5 Biological: Shan5
Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine


Ages Eligible for Study:   6 Weeks to 8 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy children in the age group six to eight weeks
  • Born after a normal gestational period (36 - 42 weeks)
  • Mother's HBsAg assured negative.
  • Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form.
  • Parents willing to fill the Diary Card

Exclusion Criteria:

  • Administration of immunoglobulin or any blood products since birth.
  • Use of any investigational, on-registered drug, or vaccine other than the study vaccine (with the exception of OPV & BCG vaccine) during the study period or within 30 days preceding the first dose of the study vaccine.
  • Previous vaccination or evidence of infection with DTP.
  • History of allergic disease or reaction likely to be exacerbated by any component of the vaccine including allergy to antibiotics.
  • Major congenital or hereditary immunodeficiency.
  • Infants having evidence of disease or fever, history of allergic disease or persistent hematological, hepatic, renal, cardiac or respiratory disease and signs of a CNS disorder at the time of vaccination.
  • Infants showing any of the following reactions after any dose of study vaccine will be withdrawn for subsequent doses: body temperature more than 40.4 degree Celsius, persistent screaming or crying for 3 hours within 48 hours of vaccination, seizures, encephalopathy and hypersensitivity reaction.
  • Parent/s or guardian of subject unable to maintain diary card
  • Simultaneous participation in any other clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00617812

Deccan College of Medical Sciences
Hyderabaad, Andhra Pradesh, India, 500058
Ankur Institute of Child Health
Ahmedabad, Gujrat, India, 380009
JSS Medical College
Mysore, Karnataka, India, 570015
Institute of Child Health
Kolkata, West Bengal, India, 700017
Sponsors and Collaborators
Shantha Biotechnics Limited
Study Director: Raman Rao, MD Shantha Biotechnics Limited, Hyderabad, India
  More Information

Responsible Party: Head Clinical Research and Medical Affairs, Shantha Biotechnics Limited Identifier: NCT00617812     History of Changes
Other Study ID Numbers: SBL/DTPwHB-Hib/PMS/2007/0100
Study First Received: February 6, 2008
Last Updated: June 24, 2009

Keywords provided by Shantha Biotechnics Limited:
Hepatitis B
Haemophilus influenzae type b
Healthy infants

Additional relevant MeSH terms:
Hepatitis B
Whooping Cough
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Respiratory Tract Infections
Respiratory Tract Diseases
Clostridium Infections
Gram-Positive Bacterial Infections
Corynebacterium Infections
Actinomycetales Infections
Immunologic Factors
Physiological Effects of Drugs processed this record on March 29, 2017